N@N

ARIAD PHARMACEUTICALS INC (NASDAQ:ARIA), Up By 5.26% ($0.33) From $6.270 After BUYINS.NET Report Predicted Strength After Earni

^{Published on 2011-03-24 08:02:19 - WOPRAI}
 

March 24, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, February 16th 2011 stating that ARIAD PHARMACEUTICALS INC (NASDAQ:ARIA) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=aria&id=147535

At the time this story was written, ARIAD PHARMACEUTICALS INC (NASDAQ:ARIA) is Up By 5.26% ($0.33) From $6.270 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ARIAD PHARMACEUTICALS INC (NASDAQ:ARIA) - ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States, Europe, and Japan. The companys lead cancer product candidate, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including sarcomas, breast cancer, prostate cancer, non-small cell lung cancer, and endometrial cancer. It is also developing AP24534, an investigational pan BCR-ABL inhibitor, which is in Phase I clinical trial for the treatment of chronic myeloid leukemia, acute myeloid leukemia, and other hematologic cancers. In addition, the company is developing AP26113, an investigational anaplastic lymphoma kinase inhibitor, which is in the preclinical stage for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. Further, it has license to technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additionally, the company licenses ARGENT technology, a portfolio of cell-signaling regulation technologies to control intracellular processes with small molecules, which is useful in the development of therapeutic vaccines and gene and cell therapy products, as well as provide various tools for use in cell biology, functional genomics, and drug discovery research. ARIAD Pharmaceuticals, Inc. has a collaboration agreement with Merck & Co., Inc. for the joint development and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to prevent restenosis or reblockage of injured vessels following interventions. The company was founded in 1991 and is based in Cambridge, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ARIAD PHARMACEUTICALS INC (NASDAQ:ARIA) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net